本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
BEIJING, April 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov. Shareholders may receive a hard copy of the audited financial statements free of charge upon request. Requests should be submitted to http://ir.ccm.cn. About Concord Medical Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see http://ir.ccm.cn. Forward-Looking Statements This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
MONTREAL, April 17, 2025 /PRNewswire/ -- On April 17, 2025, the global bleeding disorders community will come together under the theme "Access for all: Women and girls bleed too" and celebrate World Hemophilia Day. Today, women and girls with bleeding disorders (WGBDs) are still underdiagnosed and underserved. The global bleeding disorders community has the power—and the responsibility—to change this. Through recognition, diagnosis, treatment, and care, the quality of life of WGBDS will improve, and the bleeding disorders community will become stronger. World Hemophilia Day logo with name, April 17 and Recognizing all bleeding disorders "Recognizing women and girls with bleeding disorders is a significant milestone for our community. In the past, they were often viewed solely as carriers rather than individuals with a bleeding disorder. It is time to fully embrace and acknowledge their experiences and struggles. Prioritizing the diagnosis and treatment of women and girls is crucial, and doing so strengthens our entire bleeding disorder community. Join us on April 17 to show your support for access for all—including women and girls." —Cesar Garrido, WFH President World Hemophilia Day 2025 is a call to action for governments, healthcare providers, and advocates worldwide to close the gaps in care for women and girls with bleeding disorders. These individuals often face delayed diagnoses, limited access to treatment, and a lack of understanding about their unique needs. By working together, we can challenge these inequities and ensure access to comprehensive care for everyone in the bleeding disorders community. This year's theme highlights the importance of equity in healthcare, shining a light on the strength, resilience, and contributions of women and girls with bleeding disorders. Through global awareness efforts, we can break the stigma, improve education, and foster better outcomes for all. World Hemophilia Day is an opportunity for individuals, organizations, and communities to come together and make a difference. Here are some ways to participate: Get social by posting about inherited bleeding disorders and raising awareness on women and girls with bleeding disorders on Facebook, Twitter, LinkedIn and Instagram using the #WorldHemophiliaDay, #WHD2025, #WeBleedToo and #LightItUpRed hashtags Support our global advocacy efforts and be a part of what we are building today for future generations by donating here Share your story on the WFH story site about how your quality of life—or the quality of life of someone you know—has changed thanks to receiving a diagnosis, treatment and care on wfh.org/whd Contact your national hemophilia and bleeding disorders association to find out how you and other members can work together on World Hemophilia Day and raise awareness about women and girls with bleeding disorders Download resources like posters and social media banners from wfh.org/whd to help build your World Hemophilia Day Campaign Send pictures, comments, or questions to the WFH at communications@wfh.org Let's join hands on April 17, 2025, to ensure that women and girls with bleeding disorders are not left behind. Together, we can create a future where Treatment For All is a reality, and equity, care, and empowerment define the lives of those living with bleeding disorders. To learn more about World Hemophilia Day, please visit wfh.org/world-hemophilia-day. The WFH would like to thank our World Hemophilia Day sponsors for their continued support: Bayer, BioMarin Pharmaceutical Inc., Biotest, CSL Behring, F. Hoffman-La Roche Ltd., Grifols, Kedrion, LFB S.A, Novo Nordisk, Octapharma, Pfizer, Regeneron, Sanofi, Sobi, and Takeda. About hemophilia and other bleeding disorders In people with bleeding disorders, the blood clotting process doesn't work properly, with the result that they can bleed for longer than normal, and some people may experience spontaneous bleeding into joints, muscles, or other parts of their bodies which can lead to developmental and permanent mobility issues. About the World Federation of Hemophilia The World Federation of Hemophilia (WFH) is a non-profit organization dedicated to improving and sustaining care for people with inherited bleeding disorders around the world. At the WFH, national member organizations (NMOs) and health care professionals (HCPs) work together to provide care for people with inherited bleeding disorders around the world. We partner with governments and hemophilia treatment centres to enhance knowledge through training and provide tools they need to identify, support and treat people living with bleeding disorders in their communities, while promoting global advocacy and collaboration to achieve our common goals. Our vision of Treatment for All is for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, or where they live. Our mission is to improve and sustain care for people with inherited bleeding disorders around the world. To find out more about the WFH, please visit www.wfh.org. Media contact: Neha Suchak, Director, Marketing & Communications, nsuchak@wfh.org, +1 514-875-7944, #2857, www.wfh.org
Virus-specific T-cell measurement is made easier to enable better understanding of immune responses in patients and management of human infectious diseases. SINGAPORE, April 17, 2025 /PRNewswire/ -- T Cell Diagnostics Pte. Ltd. ("TCD") has licensed an intellectual property (IP) and its related know-how from Duke-NUS Medical School to develop point-of-care assays that could simplify the analysis of T-cell responses. Point-of-care tests can be performed quickly and easily at the site of patient care, such as in clinics or hospitals, without the need of specialised lab equipment. They provide rapid results, helping doctors and researchers make timely decisions. TCD was established in Singapore in 2021 as a spin-off from Duke-NUS by Professor Antonio Bertoletti, Assistant Professors Nina Le Bert and Anthony Tan from Duke-NUS' Emerging Infectious Diseases Programme. Developed based on the licensed IP and its related know-how, TCD's test kits precisely measure the amount of virus-specific T cells in clinical samples by stimulating biological samples—ranging from whole blood to nasal swabs and bronchoalveolar lavage fluids—with synthetic peptides. In response to the stimulation, the T cells release chemical signals called cytokines, which can be easily measured. Assistant Professor Nina Le Bert, who is currently applying this technology in her research on samples from patients chronically infected with the Hepatitis B Virus, said: "We are impressed by the simplicity and performance of the test kit, which has allowed the testing of hundreds of patient samples with ease and precision. It is heartening to see that the interest in measuring T-cell responses induced by vaccination or infection is gaining traction as such knowledge empowers healthcare providers and researchers to better understand immune responses in patients, in turn driving innovations to improve patient care." Mr Alessandro Sidoli, CEO of T Cell Diagnostics: "We are confident that the addition of this technology to our portfolio is a major step towards achieving our goal of using T cells as a diagnostic. Our team combines deep scientific expertise with a commitment to delivering reliable, high-quality results, ensuring that our partners can confidently advance their research and clinical goals. Whether you're exploring immune responses to viral infections, vaccination, or even cancer, TCD is your trusted partner in unlocking the power of T cell immunity." TCD offers end-to-end solutions, including project management, expert consultations, and advanced research testing services. The main focus is on analysing virus-specific cellular immune responses, with a particular emphasis on infections such as HBV, HDV, Influenza, SARS-CoV-2, and Dengue. By quantifying the number and function of antigen-specific T cells, TCD provides critical insights that can guide diagnosis, treatment, and vaccine development. Operating from a state-of-the-art BSL-2 laboratory in Singapore's Biopolis, TCD is strategically positioned to serve local, regional, and international clients. Associate Professor Christopher Laing, Vice-Dean for Innovation and Entrepreneurship at Duke-NUS, said: "Innovation in science is not just about discovery—it's about turning knowledge into solutions that improve lives. Duke-NUS scientists are among the most entrepreneurial in Asia, and our culture of innovation is supportive of partnering with startups. Our collaboration with TCD exemplifies Duke-NUS' commitment to bridging academia and industry, accelerating groundbreaking discoveries from universities to patients and society." Point-of-care tests developed by T Cells Diagnostics using Duke-NUS' know-how enable better understanding of immune responses in patients and management of human infectious diseases. About Duke-NUS Medical School Duke-NUS is Singapore's flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five signature research programmes and 10 centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives. For more information, please visit www.duke-nus.edu.sg
SUZHOU, China, April 16, 2025 /PRNewswire/ -- April 12, 2025, Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM). As the exclusive CDMO partner for this program, Porton Advanced provided comprehensive process development and manufacturing services, including plasmid, lentiviral vectors and final CAR-T cell products. We successfully manufactured dozens of batches of clinical-grade investigational products for Investigator-Initiated Trials (IITs), with all batches passing quality control on the first attempt. About GMB and Tasly's Dual-Targeting CAR-T Therapy Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system, characterized by high invasiveness, frequent recurrence, and poor prognosis. P134 Cell Injection is an autologous CAR-T product targeting CD44 and/or CD133. Its mechanism of action involves specifically recognizing and binding to antigen targets that are highly and mutually exclusively expressed in primary and recurrent GBM, thereby effectively activating and prolonging T-cell lifespan to eliminate tumor cells. Porton Advanced: Accelerating Progress of Advanced Therapies Our team's expertise in cell therapy development and cGMP production ensured high-quality, on-time delivery, contributing to Tasly's continued effort in bringing innovative oncology treatments to patients worldwide. Notably, the regulatory submission achieved zero deficiencies during the CDE review, demonstrating the high compliance of our quality system and production stability. Plasmid Production: A robust two-step chromatography process enabled rapid delivery of engineering run and GMP batches, significantly shortening timelines and reducing costs. Lentivirus Production: Utilizing our proprietary LV-SMART® lentiviral suspension platform, we achieved high batch-to batch consistency, high yield, high infectious, low residual impurities as well as 30% reduced material cost with animal components free. CAR-T Production: Porton Advanced produced high-transfection-efficiency CAR-T cells meeting with all release standards, delivered over 10 IIT samples with consistent quality, which contributes to observable clinical efficacy in IIT study. Leveraging our end-to-end CDMO platform, Porton Advanced has established a deep collaboration with Tasly. We sincerely wish Tasly success in the clinical development of CAR-T pipeline and hope it will soon bring new treatment options to patients with recurrent glioblastoma. We look forward to further strengthening our partnership to accelerate the delivery of transformative therapies to patients worldwide. About Tasly Pharma As an international modern Chinese medicine enterprise, Tasly Pharma. (Stock code: 600535) is committed to developing into a leading solution provider of medicine and health services with global influence in China. With "people-oriented and precise innovation", Tasly Pharma. constantly promotes the progress of medicine and health to make every human-being can enjoy the beauty and hope of life. Headquartered in Tianjin, China, the company has more than 20 research centers worldwide and 11 production bases throughout the country. We are committed to cracking the digital code of life medicine. Adhering to the concept of "patient-centered", we pay close attention to the evolution of disease spectrum, and make precise innovations in major therapeutic fields such as cardio-cerebrovascular, digestion and metabolism, tumor immunity, and neuroscience, which sustain the healthy life experience of human beings. With a rich drug combination including modern Chinese medicine, chemical medicine and biological innovation medicine, regenerative medicine and the 4-D integrated health management solutions, we can provide service of the whole health journey including health examination, early warning, prevention, diagnosis, treatment and rehabilitation and a personalized and integrated medical solutions covering the whole disease course for each patient and family so as to meet the diverse needs of the individual life, optimize life experience and improve life quality. About Porton Advanced Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization. Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV, etc), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc) and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sq ft, equipped with 10 viral vector production lines, 12 GMP-compliant cell therapy production suites (including 2 suites for infectious donors), and a multitude of clean rooms. As of now, we have successfully supported our clients to secure 18 global IND approvals from NMPA, FDA, and Medsafe, with 5 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China. Porton Advanced is committed to a customer-centric approach, offering excellent global, end-to-end CDMO services to our clients, enabling effective drugs to benefit the public sooner.
Driving Sustainable Healthcare with "CARE" Strategy HONG KONG and SHANGHAI, March 26, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health" or "the Company", Stock Code: 1833.HK) recently released its 2024 Environmental, Social, and Governance (ESG) Report, outlining the Company's CARE sustainability strategy built on the pillars of Comprehensive Sustainability, Advanced Technology Empowerment, Robust Information Security Protection, and Extensive Social Responsibility. Guided by the principle of "Technology for Humanity, Healthcare with Warmth," Ping An Health aims to be a leading, trusted provider of healthcare and elderly care services, driving high-quality, sustainable development in the industry. CARE: Ping An Health's Blueprint for Sustainable Development Comprehensive Sustainability Ping An Health has deeply integrated the sustainable development concept into its enterprise strategy and daily operations, establishing a three-level governance structure for sustainable development from the decision-making level to the execution level. This structure ensures the effective implementation of sustainable development goals. The Company's "Sustainable Development Strategy, Goals, and Action Plan" provides a framework for regularly tracking progress. To further strengthen medical quality control, Ping An Health has established the Pharmaceutical Quality and Safety Management Committee, under which the Medical Quality and Safety Management Task. Medical service quality, which has covered 100% of employees, ensures the efficient and effective management of pharmaceutical quality and safety. Ping An Health is committed to delivering exceptional service and setting new industry benchmarks. In 2024, Ping An Family Doctor successfully obtained the dual certification of the Digital Health Certification (DHC) and Continuing Professional Development (CPD) Training Program from the World Organization of Family Doctors (hereinafter referred to as "WONCA"), becoming the first medical health and elderly care service enterprise in the world to have the dual certification of WONCA. The WONCA certification is an authoritative certification in the field of global family medicine, and its certification standards are consistent with the guidelines of WHO, which is internationally authoritative. Furthermore, Ping An Family Doctor's service standards and telemedicine management communications are certified by the General Practice Branch of Chinese Medical Association and the Royal Australian College of General Practitioners (RACGP). WONCA Dual Certification Award Ceremony Advanced Technology Empowerment Amidst the wave of digital transformation, Ping An Health is pioneering innovative business models and breakthroughs in artificial intelligence to create a comprehensive smart medical service system, injecting new momentum into the industry's high-quality development. In 2024, the Company officially launched its self-developed large multi-modal model Ping An Medical Master. Built on hundreds of billions of parameters, this model powers Ping An Doctor's Home, an intelligent doctor's workstation comprising 12 AI subsystems. Data shows that the system achieves a Class A rate for electronic medical records of 99.8% and the accuracy rate for medication compliance reached 100%, contributing to a closed-loop health management system covering prevention, diagnosis, treatment, and rehabilitation. Furthermore, the Company launched Ping An Xin Yi, an AI-assisted expert health consultation service, providing 24/7 AI-assisted health consultations. Looking ahead, the Company will continuously advance the process of improving medical service access and creating health records for Ping An Group's 240 million retail financial customers. Moreover, the Company will fully leverage its unique advantage in closed-loop health care and insurance data to accelerate the application of large AI models in scenarios including multidisciplinary team (MDT) consultations on complex diseases. "Ping An Doctor’s Home" doctor's workstation Robust Information Security Protection Data security and privacy protection are critical foundations for Ping An Health's sustainable development. In 2024, Ping An Health obtained multiple information security management system certifications, including ISO 27001 information security management system certification, ISO 27701 privacy information management system certification, ISO 27799 personal medical health information security management system certification, covering 100% of the Company's business. The Company also continues to focus on building fundamental information security capabilities. It replaced its web application firewall (WAF) system with a domestically developed solution and further enhanced the extended detection and response (XDR) platform, which increased the alarm detection effectiveness of our original commercial products by 35%. Furthermore, Ping An Health conducts regular information security emergency drills and employee security awareness training to ensure effective data security and user privacy protection. During the reporting period, the Company conducted a total of nine information security emergency response activities, including the 2024 National Network Protection Practical Attack and Defense Exercise, and two external audits of its information security policies and systems. Information Security Management System Certification (Sample) Extensive Social Responsibility Ping An Health has always adhered to the development vision of "providing every enterprise with a harmonious workplace, every family with a dedicated doctor, and every user with a safe and healthy life", actively fulfilling its social responsibility. The Company is committed to empowering national health through inclusive healthcare initiatives. In 2024, Ping An Health launched the "Yilu Jianxing" national health literacy promotion action, reaching communities, insurance companies, and enterprises with over 40 expert-led science popularization live broadcasts and 29 health education and medical public welfare activities. Furthermore, Ping An Health enhances the accessibility and affordability of medical services by providing remote healthcare options. Ping An Health "Yilu Jianxing" Lauch Ceremony "Looking ahead, Ping An Health will continue to be guided by its CARE sustainability strategy, deepening technological empowerment, strengthening data security, and fulfilling its social responsibility to promote the high-quality development of the healthcare industry," says Li Dou, Chairman and CEO of Ping An Health. "We believe that by systematically building a sustainable development ecosystem, Ping An Health will contribute even more to achieving the 'Healthy China' strategic goal."
KUALA LUMPUR, Malaysia, March 1, 2025 /PRNewswire/ -- For the first time, Hospital Kuala Lumpur (HKL) is proudly hosting the annual Rare Disease Day 2025 celebration to raise awareness and advocate for individuals affected by rare diseases in Malaysia. This milestone event is organized by the Department of Genetics, Hospital Kuala Lumpur, in collaboration with Pharm-D Health Science, the main sponsor, alongside various patient advocacy groups. With the theme "More Than You Can Imagine", this global initiative aims to highlight the challenges faced by rare disease patients, including delays in diagnosis, limited access to genetic testing, and the high cost of treatment. Speaking at the event, Dato' Dr. Harikrishna a/l K. Ragavan Nair, Director of Hospital Kuala Lumpur, emphasized the need for stronger policies and diversified funding options to improve access to genetic testing and treatment for rare disease patients. "Rare diseases impact more individuals than we realize – 1 in 17 people worldwide. This means that each of us likely knows someone living with a rare disease, whether they are a family member, a colleague, or a friend. Today's event is not just a celebration but a movement that brings together healthcare professionals, researchers, policymakers, patient advocacy groups, and industry leaders to work towards better diagnosis, treatment, and quality of life for these patients," said Dato' Dr. Harikrishna. This year's Rare Disease Day celebration emphasizes the need for equity in healthcare, support, and opportunities for the rare disease community in Malaysia. With many Malaysians affected by rare diseases, ensuring fair access to timely diagnosis, treatment, and social inclusion is more crucial than ever. Head of the Genetics Department Hospital Kuala Lumpur, Dr. Ngu Lock Hock, further underscored the importance of collective efforts in supporting rare disease patients. "Malaysia officially defined rare diseases in 2020 as life-threatening or chronically debilitating conditions affecting fewer than 1 in 4,000 individuals. Over 70% of rare diseases are genetic, and many cases involve children. At HKL's Genetics Department, we have provided consultations to over 10,000 families and conduct around 1,000 genetic tests annually. These efforts are made possible through the strong support and commitment of the Ministry of Health, Hospital Kuala Lumpur, Hospital Tunku Azizah, as well as collaborations with various departments, NGOs, patient organizations, industry partners, and the private sector. Moving forward, strengthening these collaborations will be key to improving timely diagnosis and expanding access to treatment for rare disease patients," he shared. As part of the initiative to improve rare disease awareness, the event also marked the launch of three new books tailored for patients and caregivers: "Buku Resipi Rendah Protein untuk Pesakit Inherited Metabolic Disorders (IMD)", produced through a collaboration between HKL's dietitians and the Genetics Department, with printing support from Pharm-D Health Science. "Pengembaraan Morquio A" and "Mia & Penjelajahan MPS 6", engaging comic-style books that are designed to help children with Morquio Syndrome and Mucopolysaccharidosis type 6 (MPS VI) to better understand their condition. Pharm-D Health Science supported this event through its JARANG Program, a corporate social responsibility (CSR) initiative aimed to raise awareness, provide support, and empower individuals and families affected by rare diseases in Malaysia. Mr. Wong Chin Cheang, Managing Director of Pharm-D Health Science, expressed the company's commitment to bridging healthcare gaps in the rare disease community. "Pharm-D Health Science believes in empowering the rare disease community through innovation and collaboration. Through the JARANG Program, we are dedicated to supporting awareness campaigns like today's event. Together, we can drive meaningful change and make a lasting impact on patients' lives," said Mr. Wong. A highlight of the event was the mock cheque handover ceremony, where AGTC Genomics sponsored and Pharm-D Health Science supported the contribution of RM75,000 worth of whole exome sequencing (WES) tests for underprivileged patients. This funding will enable critical genetic testing, which is often a significant financial burden for affected families. As the event concluded, Dr. Ngu called for continued collaboration to improve the lives of rare disease patients. "Together, we can make a difference – by listening, understanding, and taking action to bring hope to the rare disease community." From the right: Mr. Wong Chin Cheang (Managing Director of Pharm-D Health Science) and Prof Leong Chee Onn (CEO of AGTC Genomics) presenting a Whole Exome Sequencing genomic tests sponsorship worth RM 75,000 to Dr. Ngu Lock Hock (Head of Department of Genetics, Hospital Kuala Lumpur) (Left), witnessed by Dato’ Dr. Harikrishna K. R Nair (Pengarah Hospital Kuala Lumpur) and Dr. Shamsul Anuar bin Kamarudin (Pengarah Hospital Tunku Azizah).
diagnosis & treatment
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
